Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
Latest in Cardiology from ACC.org
- Procedure-Related Infective Endocarditis is Rare, Not Associated With Antibiotic Prophylaxis DosingThere was so significant association between antibiotic prophylaxis (ABP) dosing before congenital cardiac catheterization and early infective endocarditis (IE) post procedure, according to a retrospective analysis recently published in JACC: Advances. Overall, IE was rare and largely dependent on procedure type.
- The Importance of Enhanced Radiation Protections in Cath LabsIn this week’s View, Dr. Eagle looks at age, body mass index (BMI), and cardiovascular outcomes after transcatheter aortic valve replacement (TAVR).
- AI-Enabled CCTA Reveals Premature Plaque Burden in South AsiansSouth Asians (SA) in the United States carry a higher burden of atherosclerotic cardiovascular disease (ASCVD) than other ethnic groups, and standard risk prediction tools often fail to capture this elevated risk.
- ACCEL Lite: The Case For Medically Tailored MealsIn this interview, Matthew W. Martinez MD, FACC and Laurence S. Sperling, MD, FACC discuss “Prescribing Meals, Not Just Meds: The Case For Medically Tailored Mealsâ€.
- FDA Update: Agency Approves First Oral PCSK9 Inhibitor to Treat High CholesterolThe U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).